Asset Details
Do you wish to reserve the book?
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Do you wish to request the book?
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Overview
Inhibition of mitogen-activated protein kinase resulted in an increase in expression of the sodium–iodide symporter in 12 of 20 patients, 8 of whom had sufficient uptake to warrant treatment with radioiodine. Five patients had a response, and 3 had stable disease.
Metastatic disease is the most frequent cause of death related to thyroid cancer.
1
Radioiodine (iodine-131) remains a mainstay of therapy for patients with metastatic thyroid cancer of follicular origin (i.e., papillary thyroid cancer or follicular thyroid cancer). Unfortunately, many patients have tumors that do not concentrate iodine, resulting in radioiodine resistance and a poor prognosis (the 10-year survival rate among patients with metastatic thyroid cancer that retains radioiodine avidity is approximately 60%, whereas it is only 10% if the metastases are refractory to radioiodine therapy).
2
Several trials have evaluated strategies to “redifferentiate” metastatic thyroid cancers and render them responsive to . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Biological and medical sciences
/ Female
/ Humans
/ Iodine
/ Iodine Radioisotopes - pharmacokinetics
/ Iodine Radioisotopes - therapeutic use
/ Kinases
/ Male
/ MAP Kinase Kinase 1 - antagonists & inhibitors
/ MAP Kinase Kinase 2 - antagonists & inhibitors
/ Mitogen-Activated Protein Kinases - metabolism
/ Mutation
/ Non tumoral diseases. Target tissue resistance. Benign neoplasms
/ Patients
/ Positron emission tomography
/ Sodium
/ Thyroid Neoplasms - genetics
/ Thyroid Neoplasms - pathology
/ Thyroid Neoplasms - radiotherapy
/ Thyroid. Thyroid axis (diseases)
/ Thyrotropin Alfa - pharmacology
/ Tumors
We currently cannot retrieve any items related to this title. Kindly check back at a later time.